SCHEMBL6358889

SCHEMBL6358889

O=C(NCc1ccc(Cl)cc1)c1ccccc1Cl

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
LMNA P02545 2/20 0.65
HPGD P15428 4/20 0.63
HTT P42858 2/20 0.63
L3MBTL1 Q9Y468 2/20 0.63
GAA P10253 1/20 0.63
ATM Q13315 1/20 0.63
APEX1 P27695 1/20 0.60
GFER P55789 1/20 0.59
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
PPARG P37231 1/20 0.58
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
TDP1 Q9NUW8 1/20 0.56
KDM4E B2RXH2 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CYP1A2 P05177 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5860823 0.90 NPC1 (0.71) ALDH1A1LMNAHPGDL3MBTL1GAA
SCHEMBL15686619 0.87 KMT2A (0.70) ALDH1A1LMNAHPGDHTTL3MBTL1
SCHEMBL26921872 0.87 APEX1 (0.57) ALDH1A1LMNAHPGDL3MBTL1APEX1
SCHEMBL15686093 0.87 HPGD (0.68) ALDH1A1LMNAHPGDAPEX1GFER
SCHEMBL17339231 0.84 TRPV1 (0.58) ALDH1A1LMNAHPGDAPEX1GFER
SCHEMBL14727423 0.84 ALDH1A1 (0.73) ALDH1A1LMNAHPGDHTTL3MBTL1
SCHEMBL2453957 0.84 GFER (0.83) ALDH1A1LMNAHPGDHTTL3MBTL1
SCHEMBL4182426 0.84 ALDH1A1 (0.62) ALDH1A1LMNAHPGDHTTL3MBTL1
SCHEMBL6358333 0.84 HPGD (0.62) ALDH1A1LMNAHPGDAPEX1GFER
SCHEMBL11628798 0.84 MAPK1 (0.68) ALDH1A1HPGDHTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed
CN-1033797-A The N-phenylalkylbenzamidefungicides fungicides LILLY CO ELI (US) 1989-07-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 ALDH1A1 1194/4885LMNA 1197/4885HPGD 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.